Abstract：Objective To explore the application of restricted mean survival time regression model to analysis of survival data. Methods Pseudo-value regression method was used to implement restricted mean survival time regression in real medical data, and then a comparison with common survival analysis models was conducted. Results The restricted mean survival time regression model without specific hypothesis was applicable to the survival data which did not meet the assumption of proportional hazards. Real case analysis displayed that the restricted mean survival time model was flexible. By setting different tau values, mean survival time could be estimated in different time periods. The results gave an intuitive explanation and provided practical conclusions in clinical practice. Conclusions In the case that the proportional risk hypothesis is not satisfied and the survival curves cross, the restricted mean survival time model can provide stable, effective estimation and straightforward interpretation, which illuminates effective applicability in the field of survival analysis and can be used as a supplement to analysis results of the Cox proportional risk model.
柳芳超, 姜晓颖, 姜慧, 张迪, 郑晓静, 弭凤玲. 限制平均生存时间回归模型在生存分析中的应用[J]. 实用预防医学, 2020, 27(11): 1391-1395.
LIU Fang-chao, JIANG Xiao-ying, JIANG Hui, ZHANG Di, ZHENG Xiao-jing, MI Feng-ling. Application of restricted mean survival time regression model to survival time analysis. , 2020, 27(11): 1391-1395.
[1] Uno H, Wittes J, Fu H, et al. Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies[J]. Ann Intern Med,2015,163(2):127-134. [2] Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis[J]. J Clin Oncol,2014,32(22):2380-2385. [3] Trinquart L, Jacot J, Conner SC, et al. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials[J]. J Clin Oncol,2016,34(15):1813-1819. [4] Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome[J]. BMC Med Res Methodol,2013,13:152. [5] Wang ZX, Wu HX, Xie L, et al. Correlation of milestone restricted mean survival time ratio with overall survival hazard ratio in randomized clinical trials of immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Netw Open,2019,2(5):e193433. [6] 杨紫荆,吕晶晶,侯雅文,等. 限制平均生存时间在临床随访研究中的应用[J]. 中华流行病学杂志,2019,40(2):247-250. [7] Orkaby AR, Rich MW, Sun R, et al. Pravastatin for primary prevention in older adults: restricted mean survival time analysis[J]. J Am Geriatr Soc,2018,66(10):1987-1991. [8] A'Hern RP. Cancer biology and survival analysis in cancer trials: restricted mean survival time analysis versus hazard ratios[J]. Clin Oncol (R Coll Radiol),2018,30(9):e75-e80. [9] Lambert P, Collett D, Kimber A, et al. Parametric accelerated failure time models with random effects and an application to kidney transplant survival[J]. Stat Med,2004,23(20):3177-3192. [10] 师成虎,余红梅,王彤,等. 加速失效时间模型及其医学应用[J]. 现代预防医学,2004,31(4):490-492. [11] Andersen PK, Hansen MG, Klein JP. Regression analysis of restricted mean survival time based on pseudo-observations[J]. Lifetime Data Anal,2004,10(4):335-350. [12] Andersen PK, Klein JP, Rosthøj S. Generalised linear models for correlated pseudo-observations, with applications to multi-state models[J]. Biometrika,2003,90(1):15-27. [13] Molinaro AM, Simon R, Pfeiffer RM. Prediction error estimation: a comparison of resampling methods[J]. Bioinformatics,2005,21(15):3301-3307. [14] Liang K, Zeger SL. Longitudinal data analysis using generalized linear models[J]. Biometrika,1986,73(1):13-22. [15] Tian L, Zhao L, Wei LJ. Predicting the restricted mean event time with the subject's baseline covariates in survival analysis[J]. Biostatistics,2014,15(2):222-233. [16] Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models[J]. Am J Epidemiol,2008,168(6):656-664. [17] Zucker DM. Restricted mean life with covariates: modification and extension of a useful survival analysis method[J]. J Am Stat Assoc,1998,93(442):702-709. [18] Liang F, Zhang S, Wang Q, et al. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer[J]. Ann Oncol,2018,29(5):1320-1324. [19] Huang B, Kuan PF. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point[J]. Pharm Stat,2018,17(3):202-213.
2020, Vol. 27 
